| Literature DB >> 33633828 |
Seung-Eun Lee1, Sung Woon Park2, Min Sun Choi1, Gyuri Kim1, Jee Hee Yoo3, Jiyeon Ahn4, Ji Eun Jun5, Hong Suk Park6, Dongho Hyun6, Sung Ki Cho6, Seong Eun Ko6, Beom-Jun Kim7, Jong Woo Kim8, Hyun-Ki Yoon8, Jung-Min Koh7, Seung Hun Lee9, Jae Hyeon Kim10.
Abstract
BACKGROUND AND AIMS: Frequent failure of adrenal vein (AV) cannulation is a major obstacle to the universal use of adrenal vein sampling (AVS) for subtyping primary aldosteronism (PA). This study aimed to confirm and modify the value of a previously reported AVS parameter for PA subtyping in the case of cannulation failure on one side.Entities:
Keywords: adrenal vein sampling; lateralization index; primary aldosteronism; subclinical hypercortisolism
Year: 2021 PMID: 33633828 PMCID: PMC7887669 DOI: 10.1177/2042018821989239
Source DB: PubMed Journal: Ther Adv Endocrinol Metab ISSN: 2042-0188 Impact factor: 3.565
Figure 1.Study population (patient number).
aSubclinical hypercortisolism is defined by the following: (1) cortisol level after 1 mg DST ⩾5 µg/mL or (2) cortisol level after 1 mg DST >2.2 µg/dL with the presence of either low levels of adrenocorticotropic hormone (<10 pg/mL) or dehydroepiandrosterone-sulfate (<80 μg/dL in males or <35 μg/dL in females).
bConfirmed primary aldosteronism from saline infusion test when post-saline infusion plasma aldosterone concentration >5ng/dL.
cSuccessful catheterization in both sides is defined by the cortisol ratio of each adrenal vein to inferior vena cava ⩾5.
1 mg DST = 1 mg overnight dexamethasone suppression test.
AMC, Asan Medical Center; PA, primary aldosteronism; SMC, Samsung Medical Center.
Baseline characteristics of study population.
| AMC | SMC | Total | ||
|---|---|---|---|---|
| Derivation cohort | Validation cohort | |||
|
| 121 | 36 | 157 | |
| Age, years | 53.2 ± 10.3 | 49.8 ± 13.1 | 0.098 | 52.4 ± 11.1 |
| Male | 64 (52.9%) | 25 (69.4%) | 0.078 | 89 (56.7%) |
| BMI, kg/m2 | 25.9 ± 3.7 | 25.4 ± 3.3 | 0.410 | 25.8 ± 3.6 |
| SBP, mmHg | 141.8 ± 17.2 | 144.4 ± 18.8 | 0.436 | 142.4 ± 17.5 |
| DBP, mmHg | 86.9 ± 11.4 | 86.8 ± 11.8 | 0.961 | 86.9 ± 11.4 |
| PAC, ng/dL | 25.4 (20.1–31.3) | 25.6 (13.0–41.0) | 0.859 | 25.4 (19.8–32.0) |
| PRA, ng/ml per h | 0.2 (0.2–0.5) | 0.2 (0.1–0.5) | 0.170 | 0.2 (0.2–0.5) |
| ARR | 102.5 (54.3–170.0) | 85.2 (44.6–256.0) | 0.959 | 100.0 (53.3–186.9) |
| K, mmol/L | 3.9 ± 0.5 | 3.6 ± 0.4 | 0.001 | 3.8 ± 0.5 |
| K supplement | 36 (29.8%) | 25 (69.4%) | <0.001 | 61 |
| DDD | 1.5 (0.8–2.8) | 3.0 (2.0–4.0) | 0.001 | 2.0 (1.0–3.0) |
| Size, cm | 1.5 ± 0.7 | 1.6 ± 0.5 | 0.670 | 1.5 ± 0.6 |
| Lateralization | <0.001 | |||
| Right | 19 (15.7%) | 13 (36.1%) | 32 (20.4%) | |
| Left | 31 (25.6%) | 11 (30.6%) | 42 (26.8%) | |
| Bilateral | 70 (57.9%) | 9 (25.0%) | 79 (50.3%) | |
| Indeterminate | 1 (0.8%) | 3 (8.3%) | 4 (2.5%) | |
| Adrenalectomy | 59 (48.8%) | 23 (63.9%) | 0.111 | 82 (52.2%) |
| Pathology | 0.685 | |||
| Adenoma | 53 (89.8%) | 22 (95.7%) | 75 (91.5%) | |
| Hyperplasia | 5 (8.5%) | 1 (4.3%) | 6 (7.3%) | |
| Both | 1 (1.7%) | 0 (0.0%) | 1 (1.2%) |
Categorical variables are presented as number (%), continuous variables as mean ± SD or median (interquartile range) according to distribution.
Lateralization of primary aldosteronism is determined by lateralization index, side-to-side ratio of aldosterone to cortisol ratio.
AMC, Asan Medical Center; ARR, aldosterone to renin activity ratio; BMI, body mass index; DBP, diastolic blood pressure; DDD, daily defined dose; PAC, plasma aldosterone concentration; PRA, plasma renin activity; SBP, systolic blood pressure; SMC, Samsung Medical Center.
LIR and RIR according to lateralization.
| Lateralization | Derivation cohort | Validation cohort | Total | ||||
|---|---|---|---|---|---|---|---|
| LIR | 218 | 34 | 252 | ||||
| Right | 33 | 0.5 (0.3–0.6) | 13 | 0.2 (0.2–0.5) | 46 | 0.4 (0.2–0.6) | |
| Left | 58 | 4.1 (3.1–5.8) | 10 | 6.8 (2.5–9.3) | 68 | 4.2 (2.8–6.9) | |
| Bilateral | 126 | 2.5 (1.6–3.0) | 8 | 2.1 (1.3–4.1) | 134 | 2.5 (1.6–3.0) | |
| Indeterminate | 1 | 3.8 | 3 | 2.0 (0.3–3.5) | 4 | 2.7 (1.1–3.6) | |
| RIR | 228 | 44 | 272 | ||||
| Right | 38 | 4.7 (4.0–6.5) | 15 | 5.6 (2.8–11.2) | 53 | 5.0 (3.9–7.0) | |
| Left | 59 | 0.2 (0.2–0.4) | 15 | 0.3 (0.1–0.6) | 74 | 0.2 (0.2–0.5) | |
| Bilateral | 130 | 2.5 (1.7–3.2) | 10 | 2.4 (1.4–2.7) | 140 | 2.5 (1.7–3.2) | |
| Indeterminate | 1 | 1.2 | 4 | 0.7 (0.6–0.9) | 5 | 0.8 (0.6–0.9) |
Values are presented as median (interquartile range).
There is no significant difference in comparison of LIR or RIR between both groups (Mann–Whitney test). There is no significant difference in cortisol level at each site of inferior vena cava (IVC), left adrenal vein (LAV), and right adrenal vein (RAV) between LIR and RIR (data not shown). Lateralization is determined by lateralization index (LI) as follows: LI >4, right or left; LI <3, bilateral; LI 3–4 indeterminate. LIR is aldosterone/cortisol ratio (ACR) of LAV to IVC (ACR of LAV/ACR of IVC ratio) and RIR is ACR of RAV to IVC (ACR of RAV/ACR of IVC ratio).
Figure 2.Logarithmic plotting of LIR and RIR with respect to lateralization. Numbers above and below lines present cutoff values of LIR and RIR, respectively. LIR cutoff for lateralization: >5.4 or <0.5; RIR cutoff for lateralization: >7.0 or <0.5. LIR is aldosterone/cortisol ratio (ACR) of left adrenal vein (LAV) to inferior vena cava (IVC) (ACR of LAV/ACR of IVC ratio) and RIR is ACR of right adrenal vein (RAV) to IVC (ACR of RAV/ACR of IVC ratio).
Evaluation of Scatterplot cutoffs and Pasternak’s cutoffs (⩽0.5, ⩾5.5) for the current study’s cohort for prediction of unilateral (either ipsilateral or contralateral) aldosterone hypersecretion.
| A. | ||||||
|---|---|---|---|---|---|---|
| LIR (<0.5, >5.4) | RIR (<0.5, >7.0) | |||||
| Derivation cohort | Validation cohort | Total | Derivation cohort | Validation cohort | Total | |
|
| 218 | 34 | 252 | 228 | 44 | 272 |
| Sensitivity | 36.3 | 65.2 | 42.1 | 55.7 | 53.3 | 55.1 |
| Specificity | 100 | 81.8 | 98.6 | 100 | 85.7 | 98.6 |
| PPV | 100 | 88.2 | 96 | 100 | 88.9 | 97.2 |
| NPV | 68.6 | 52.9 | 67.3 | 75.3 | 46.2 | 71.5 |
| B. | ||||||
| LIR (⩽0.5, ⩾5.5) | RIR (⩽0.5, ⩾5.5) | |||||
| Derivation cohort | Validation cohort | Total | Derivation cohort | Validation cohort | Total | |
| Sens | 37.4 | 65.2 | 43.0 | 66.0 | 56.7 | 63.8 |
| Spec | 99.2 | 81.8 | 97.8 | 96.9 | 78.6 | 95.2 |
| PPV | 97.1 | 88.2 | 94.2 | 94.1 | 85.0 | 92.0 |
| NPV | 68.9 | 52.9 | 67.5 | 79.4 | 45.8 | 75.0 |
Values are presented as %.
LIR is aldosterone/cortisol ratio (ACR) of left adrenal vein (LAV) to inferior vena cava (IVC) (ACR of LAV/ACR of IVC ratio) and RIR is ACR of right adrenal vein (RAV) to IVC (ACR of RAV/ACR of IVC ratio).
NPV, negative predictive value; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.
Figure 3.Application of various cutoffs to the total study cohort. LIR is aldosterone/cortisol ratio (ACR) of left adrenal vein (LAV) to inferior vena cava (IVC) (ACR of LAV/ACR of IVC ratio) and RIR is ACR of right adrenal vein (RAV) to IVC (ACR of RAV/ACR of IVC ratio).
ROC, receiver operating characteristic; Sens, sensitivity; Spec, specificity.